Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Sandra R. Brave(Tokyo Medical and Dental University), Simon T. Barry(AstraZeneca (Singapore))
Cited by 88
Related Papers
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
|Advanced Drug Delivery Reviews|2016|1.1k
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
|Journal for ImmunoTherapy of Cancer|2018|87